We further found that pharmacologically modulating either NR2B extrasynaptic expression or activity yielded a reduction in AD-tau aggregation, whereas the combined pharmacological treatment revealed a deleterious effect on tau burden. This evidence concerns the gene GRIN2B and Alzheimer disease.